Background: Current staging systems for unresectable or metastatic neuroblastoma do not reliably predict responses to chemotherapy in infants under 1 year of age. Previous studies have indicated that the DNA content, or ploidy, of malignant neuroblasts can discriminate between good and poor responders in this group of patients, but the clinical utility of ploidy assessment has remained in question. Purpose: We tested, in a prospective nonrandomized study, the hypothesis that neuroblast ploidy could be used as the sole guide for treatment selection in infants with unresectable or metastatic tumors and could differentiate between those who would respond to our previous standard regimen and those who would benefit from an immediate switch to another therapy. Methods: One hundred seventy-seven infants were enrolled in this trial. Five of these infants were subsequently excluded (two ineligible, two lacking ploidy information, and one protocol violation); therefore, 172 patients were included in the study. Nineteen (46%) of 41 assessable infants with diploid tumors were complete responders. The overall 3-year survival estimate for this group was 55% (95% CI = 39%-70%). Prognostic factor analysis indicated that NMYC gene amplification and an elevated serum lactate dehydrogenase level were statistically significant markers of higher risk disease within the diploid group (two-sided P values of .005 and .003, respectively). Only NMYC was predictive in the hyperdiploid group (P = .003). Conclusion: Use of a prognostic staging
The assessment of tumor cell biology and its relation to prognosis has been at the heart of efforts to improve therapy for the childhood cancers (1, 2) . Indirect measures of biologic heterogeneity-such as tumor size, primary site, degree of tumor progression, and histopathology-have all been used to devise staging systems and predict outcome, but none has provided a precise guide to clinical management (2) (3) (4) (5) (6) (7) . Observations made during the past decade indicate that genetic changes underlie the expression and maintenance of malignant phenotypes and are largely responsible for the extensive diversity of tumor cells (8, 9) . This suggests that tumor staging based on one or more genetic features could offer prognostic discrimination not available through unmodified clinicopathologic systems and thus could aid in the choice of the most appropriate therapy for individual patients.
Neuroblastoma arises from the adrenal medulla or other areas of the sympathetic nervous system and is the most common neoplasm affecting infants (7) . Current staging systems for unresectable or metastatic neuroblastoma do not reliably predict responses to chemotherapy in infants, particularly among those under 1 year of age. In previous studies (10, 11) , we demonstrated the ability of tumor cell DNA content (ploidy) to predict responses to chemotherapy among infants with unresectable or metastatic neuroblastoma. Infants with hyperdiploid tumors consistently became long-term survivors after well-tolerated combination chemotherapy involving administration of cyclophosphamide plus doxorubicin, whereas the vast majority of those with diploid tumors had poor responses to this treatment. Thus, we postulated that neuroblast ploidy could be used prospectively to assign patients to standard therapy (as above) or to alternative regimens.
In this nonrandomized study, cyclophosphamide plus doxorubicin was administered as primary chemotherapy to all infants with hyperdiploid tumors, while cisplatin plus teniposide was selected for those with diploid tumors on the basis of its promising activity against resistant neuroblastoma (12) . We also assessed the prognostic role of NMYC gene amplification (11, 13) and more commonly measured prognostic variables within our ploidy-based treatment systems.
Patients and Methods

Patients
Infants under 1 year of age with previously untreated metastatic or unresectable neuroblastoma were eligible for Pediatric Oncology Group (POG) study 8743, in which patients were enrolled from May 1987 to October 1991. Minimum and maximum follow-up times were 18 days and 8.9 years, respectively (median, 5.6 years). The diagnosis of neuroblastoma was based on histologic examination of tumor specimens (or of bone marrow samples in the case of patients with increased catecholamine levels) and an abdominal or thoracic mass suggestive of neuroblastoma. All diagnoses were confirmed by the coordinating pathologist (V. Joshi). Postoperative staging followed criteria of the Pediatric Oncology Group (14) 
Studies of Tumor Cell Biology
Tumor or bone marrow samples containing greater than 10% malignant cells were shipped to St. Jude Children's Research Hospital and were used to determine the DNA content of neuroblasts; the DNA content then was converted to a DNA index (ratio of the modal G 0 cell cycle phase/G 1 cell cycle phase DNA content for neuroblastoma cells versus that of normal diploid cells) (10, 11) . A DNA index of approximately 1.0 corresponds to a diploid chromosome number; an index greater than 1.0 denotes hyperdiploidy. In patients with multiple stem lines, the line with the lowest DNA index was used for staging purposes. The heterogeneity of DNA content measurements within the hyperdiploid groups has not shown prognostic significance in neuroblastoma (10) and was therefore not considered a major source of response variability in this study. The lowest DNA index in a nondiploid tumor was 1.08.
The NMYC gene copy number was determined by Southern blot analysis in tumor specimens submitted to the Washington University School of Medicine, St. Louis, MO, as described previously (11, 13, 16) . Briefly, tumor DNA was digested, hybridized to the 2.0-kilobase pNb-1 probe for the NMYC oncogene (17) , and radiolabeled (18) . NMYC copy number was determined by serial dilution and laser densitometry. The gene was considered unamplified if the copy number was less than or equal to 3 per haploid genome and amplified if the number was greater than 3. Serum levels of lactate dehydrogenase (LDH) (19) and ferritin (20) were measured at participating institutions.
Response Definitions
A complete response was defined as a greater than 90% regression of tumor at the primary site with complete regression of all metastatic disease, including healing of bone lesions (i.e., decreased uptake of 99 technitium-diethylenetriaminepentaacetic acid or resolution of lytic lesions on plain roentgenograms). A partial response was considered to be a decrease greater than or equal to 50% but less than or equal to 90% in the volume of the primary tumor, with a greater than 50% decrease in the combined mass of all measurable metastatic lesions except bone lesions, no evidence of progression of any lesion, and no development of new disease. A partial response of bone metastases was defined as no increase in size or number of lesions by analysis of radiographic bone scan or plain roentgenograms. Minimum time to qualify as a response was 4 weeks. Patients not meeting the criteria for a complete or partial response were considered nonresponders, including those with a partial response at one site and progressive disease or no response at another site.
Treatment Plan
One hundred seventy-seven infants were enrolled in this trial. Five of these infants were subsequently excluded (two ineligible, two lacking ploidy information, and one protocol violation). Thus, data are presented for 172 patients. During the interval from diagnosis to measurement of tumor cell ploidy, all patients were treated with a single course of cyclophosphamide (Cytoxan; Bristol-Myers Squibb, Princeton, NJ) at a dose of 150 mg/m 2 per day orally or intravenously for 7 days and doxorubicin (Adriamycin; Pharmacia, Dublin, OH) at a dose of 35 mg/m 2 intravenously on day 8, as previously described (10, 11, 21) . They were then assigned to one of two treatment arms according to the ploidy classification of their tumors.
Hyperdiploid group. One hundred thirty infants with hyperdiploid tumors received four additional courses of cyclophosphamide plus doxorubicin at 21-day intervals. Those who developed progressive disease at either a primary or a metastatic site during this therapy were immediately switched to cisplatin (Platinol; Bristol-Myers Squibb) at a dose of 90 mg/m 2 intravenously on day 1 followed by teniposide at a dose of 100 mg/m 2 intravenously on day 3. Patients were eligible for second-look surgery if they had complete resolution of metastatic tumor in all sites (except the liver, where a partial response was acceptable) and if the primary tumor appeared to be at least 50% resectable. Those with grossly resected tumors and no evidence of residual disease were considered complete responders and had their therapy discontinued. Those with greater than 50% but less than gross total resections, evidence of active disease in nonadherent lymph nodes, or residual neuroblastoma or ganglioneuroblastoma detected by liver biopsy received two additional courses of cisplatin plus teniposide, followed 21 days later by cyclophosphamide plus doxorubicin. Patients who were not eligible for second-look surgery were considered to have nonresponsive tumors and thus were switched to the cisplatin plus teniposide regimen.
Diploid group. After their initial course of therapy with cyclophosphamide plus doxorubicin, 42 infants with diploid tumors were treated with cisplatin (90 mg/m 2 intravenously on day 1) and teniposide (100 mg/m 2 intravenously on day 3). Those with progressive disease at any time after the first two courses were declared treatment failures on cisplatin plus teniposide. Second-look surgery was performed after patients had received five courses of primary chemotherapy according to the same criteria that were applied to the hyperdiploid group. Patients who were ineligible for surgery received two additional courses of cisplatin plus teniposide and then were re-evaluated. Treatment was discontinued for patients with surgical evidence of a complete response; all other patients received three additional courses of cisplatin plus teniposide.
Trimethoprim plus sulfamethoxazole prophylaxis on a 3-day-per-week schedule (150 mg/m 2 of trimethoprim orally divided twice a day) for prevention of Pneumocystis carinii pneumonitis was recommended for all patients.
Toxicity Monitoring
During treatment, each child was tested regularly for cardiac or renal dysfunction and for other types of toxic effects. Follow-up surveillance included echocardiographic studies at 7 months, 1 year, and 2 years after the completion of therapy. Whenever possible, to measure ototoxicity, brain-stem audiometry was conducted at these intervals in children treated with cisplatin plus teniposide. Physical examinations were performed every 2-6 months during the first 3 years after treatment and annually thereafter. Definitions of toxicity were as described in the Common Toxicity Criteria (Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, Diagnosis, and Centers, National Cancer Institute, Bethesda, MD).
Study Design/Statistical Analysis
Major considerations in planning the study were (a) the very high rate of complete responses (approximately 90%) among patients with hyperdiploid tumors treated with cyclophosphamide plus doxorubicin in the past, contrasted with the very low rate among patients with diploid tumors receiving the same combination (one responder among 15 infants treated) (11); (b) the ineffectiveness of late administration of alternative therapy in producing long-term survival in patients with disease resistant to cyclophosphamide plus doxorubicin (11) ; and (c) the expected slow accrual of patients to the diploid group. Thus, we chose a nonrandomized study design to test our central hypothesis that tumor cell ploidy measurements identify two distinct groups of patients, one (hyperdiploid) that responds well to cyclophosphamide plus doxorubicin therapy and another (diploid) that is unlikely to respond to this therapy and will require an immediate switch to an alternative combination.
The primary statistical end points in this study were the best early response to chemotherapy and overall survival, as measured from the date of diagnosis. Survival probabilities were estimated as a function of time by the method of Kaplan and Meier (22) . Unless otherwise noted, associations between candidate prognostic factors and survival were determined with the exact conditional logrank test using the StatXact Program (23) . This approach avoids reliance on asymptotic estimates, which can be unstable when the number of events is small. The adjusted odds ratios and 95% confidence intervals (CIs) for NMYC gene amplification, serum LDH level, and primary site in patients with diploid tumors were calculated by the method recommended by Peto et al. (24, 25) . Relationships between ploidy classification and presenting clinicobiologic features were tested with contingency-table chi-squared statistics. A two-sided P value of <.05 was taken to indicate statistical significance.
Results
Of the 172 infants treated in this trial, 130 (76%) had hyperdiploid tumors and 42 (24%) had diploid tumors. There was a clear difference between these groups in the distribution of tumor stages and other presenting features (Table 1 ). Whereas the majority of patients with diploid tumors had stage D disease, those in the hyperdiploid group were more likely to have stage B or C disease. Primary adrenal tumors, which have been associated with an unfavorable prognosis (26), were more common among patients with diploid tumors than among patients with hyperdiploid tumors (62% versus 36%; P ‫ס‬ .032). The NMYC copy number (determined in 126 patients; 73%) was found to be amplified in 10 patients with diploid tumors compared with only six patients with hyperdiploid tumors (33% versus 6%; P<.001). Diploid tumors were more frequent in boys (P ‫ס‬ .004) and in patients with elevated levels of serum LDH (P<.001).
Early Responses
Complete responses were induced in 115 (91%) of the 127 assessable infants with hyperdiploid tumors (three of the original 130 patients were not assessable, one because of a late protocol violation and two because of insufficient information). For 85 of these patients, the complete response resulted from treatment involving five courses of cyclophosphamide plus doxorubicin. To obtain a complete response in the other 30 patients, either cisplatin plus teniposide induction therapy (after failure to respond to the first drug combination; n ‫ס‬ 9) or continuation courses of cisplatin plus teniposide alternating with cyclophosphamide plus doxorubicin (n ‫ס‬ 21) were required. Amplification of the NMYC gene was detected in six patients with hyperdiploid tumors, two of whom were considered resistant to primary treatment. Of the 41 assessable infants in the diploid
Response rates among patients with diploid tumors did not appear to be affected by the NMYC copy number.
Survival
All 172 infants were assessable for survival. At 3 years of follow-up, an estimated 94% (95% confidence interval [CI] ‫ס‬ 89%-98%) of the patients with hyperdiploid tumors were still alive (Fig. 1) . Of the 115 patients classified as complete responders and the five classified as partial responders who completed therapy, all remain relapse free more than 2 years after diagnosis. Three of the six infants in the hyperdiploid group with amplified NMYC genes died of tumor at 7, 11, and 50 months; the other three patients are alive, off therapy, and in complete remission at 5.6, 6.0, and 6.4 years, respectively, after the initial diagnosis. The 3-year survival estimate for the diploid group was 55% (95% CI ‫ס‬ 39%-70%). Of the 30 deaths (29 from tumor), 12 occurred in patients with NMYC gene amplification; 10 other deaths were associated with a nonamplified NMYC locus, and eight were associated with an unknown NMYC status. Comparison of outcome between patients with or without amplified NMYC copies indicated significantly poorer survival in the former subgroup ( Fig. 2; P<.001 ). Only five of the 13 patients with diploid tumors and a partial response were alive at the time of analysis-two after autologous bone marrow transplantation and two after local radiotherapy; one survivor has a second cancer (renal cell carcinoma).
Prognostic Factors
A major aim of the study was to identify clinical or biologic risk factors that might augment the predictive strength of neuroblast ploidy. Among patients with hyperdiploid tumors, only NMYC gene amplification showed prognostic significance in a univariate analysis (Table 2) ; further study was not attempted because of the few deaths in the hyperdiploid group (27) . Three factors-primary tumor site, NMYC copy number, and serum LDH level-emerged as significant predictors of outcome in the univariate analysis for patients with diploid tumors ( Table 2 ). The prognostic strength of primary site became marginal (P ‫ס‬ .073) when adjustment was made for serum LDH level and disappeared when adjustment was made for NMYC gene amplification (Table 3) ; however, both of the latter features retained significance when the analysis was stratified by site (P ‫ס‬ .005 and .009, respectively). Neither NMYC gene amplification nor serum LDH level showed independent power after adjustment for each other. Although often overlapping, these features were not redundant, inasmuch as four of the 20 deaths associated with a diploid karyotype occurred in children who exhibited no amplification of NMYC loci and an elevated serum LDH level. Thus, the latter marker identified a subset of patients at higher risk whose disease would not be accurately staged by NMYC copy number alone.
Toxicity
Myelosuppression was commonly found in patients on both treatment arms, but slightly higher percentages of patients with hyperdiploid tumors who had been treated on the cyclophosphamide plus doxorubicin regimen were admitted to the hospital for febrile neutropenia (Table 4) . Infection rates associated with the two regimens were similar (38% for the diploid group versus 32% for the hyperdiploid group). Three infants with diploid tumors had a 50%-75% decrease in creatinine clearance after receiving cumulative cisplatin doses of 630 mg/m 2 , which required cessation of this treatment. Two infants with hyperdiploid tumors had a transient 50% decrease in creatinine clearance after receiving 180 mg/m 2 of cisplatin as maintenance therapy. The frequency of ototoxicity associated with cisplatin plus teniposide therapy could not be determined because of the difficulties in obtaining reliable audiometric test results in infants; however, two patients developed severe hearing loss after receiving cumulative cisplatin doses of 630 and 450 mg/m 2 and required hearing aids. Two infants who had received cumulative doxorubicin doses of 125 mg/m 2 and 245 mg/m 2 , respectively, showed grade 3 decreases in left ventricular function, as determined by echocardiography, and were treated with digoxin. Two others developed P. carinii pneumonitis while they were receiving cyclophosphamide plus doxorubicin therapy without trimethoprim plus sulfamethoxazole prophylaxis. There was a single episode of fatal sepsis, occurring in a child on the cyclophosphamide plus doxorubicin regimen.
Discussion
Age and disease stage at diagnosis have been the most influential factors for clinicians in their selection of therapies for *Values in column ‫ס‬ probability, %, of survival at 3 years after diagnosis (95% confidence interval) by Kaplan-Meier analysis; P values are from exact logrank comparisons, except for tumor stage, for which the conventional logrank test was used. †Odds of surviving for an infant with the favorable compared with the unfavorable category of a particular factor. ‡Significance level, by the exact logrank test, for the prognostic contribution of the primary factor (column 1) after adjustment for the indicated secondary factor (column 2). children with neuroblastoma. In general, complete surgical resection of localized tumors without further treatment produces a high rate of cure (14), whereas for patients with unresected or widely disseminated disease, the outlook is much less predictable. If the child with disseminated disease is older than 2 years, the probability of cure is low, regardless of the treatment used (11, 26) . By contrast, many infants younger than 1 year have long-term survival following limited or moderately intensive therapy, whereas others treated with the same regimens show initial drug resistance or relapse soon after achieving remission (10, 11, 28) . We have proposed that transformation-linked genetic abnormalities account for much of the variable prognosis of neuroblastoma in infants (10, 11) and, therefore, could be used to guide the choice of primary treatment. Our study represents, to our knowledge, the first prospective test of this hypothesis. The findings suggest that a model staging system based on tumor cell ploidy combined with NMYC copy number, serum LDH level, and perhaps other emerging biologic markers (29, 30) would very likely improve the treatment selection for infants with unresectable or metastatic neuroblastoma.
Of the 130 infants with hyperdiploid tumors, only 10 have died after treatment with cyclophosphamide plus doxorubicin, administered alone or followed by cisplatin plus teniposide (3-year survival estimate, 94%; 95% CI ‫ס‬ 89%-98%). This result prospectively confirms observations made on a smaller sample of infants in an earlier Pediatric Oncology Group study (11) . Although short-term therapy with cyclophosphamide plus doxorubicin induced neutropenia in 88% of patients with hyperdiploid tumors, this therapy caused few serious side effects. Four of the six patients with NMYC gene amplification in the hyperdiploid group attained complete responses, and only three are surviving free of disease. Thus, extra copies of the NMYC oncogene appear to be a poor prognostic sign in hyperdiploid casesone that might be used to identify the rare infant who is likely to fail on the primary regimen. In an earlier study (31) , high serum LDH levels were predictive of a poor outcome. In the univariate analysis performed in the present study, high serum LDH levels were suggestive of a poor outcome, but the association was not statistically significant (P ‫ס‬ .073); the other variables examined, including disease stage, did not appear helpful in assessing risk status within this group.
The biologic explanation for the increased chemosensitivity of hyperdiploid neuroblastoma in infants remains unclear. One possibility, raised by one recent in vitro study of hyperdiploid lymphoblastic leukemia cells (32) , would be a marked propensity to undergo apoptosis in the face of environmental stress, such as that induced by antineoplastic drugs. Another is suggested by the high levels of neurotrophin growth factor (TRK-A) secreted by hyperdiploid tumors; this factor may have an important role in neuroblastoma regression or differentiation (33) . Approximately half of the patients with diploid tumors responded fully to cisplatin plus teniposide after an initial course of cyclophosphamide plus doxorubicin; the mean survival estimate for the entire diploid group was 55% (95% CI ‫ס‬ 39%-70%). From earlier experience (10,11), we would have predicted a low complete response rate (approximately 7%) had the cyclophosphamide plus doxorubicin combination been used exclusively and a survival rate of less than 20% with instigation of salvage therapy after disease progression (11) . Although NMYC gene amplification did not predict initial responsiveness to chemotherapy in these patients, it was closely associated with survival, in agreement with retrospective analyses (5, 34) . Only one of the 10 infants who had amplified NMYC gene loci was alive at the time of analysis, compared with 14 of 20 who had diploid tumors and nonamplified NMYC loci. Results of our stratified analysis confirmed the value of NMYC gene amplification as a predictor of outcome on the cisplatin plus teniposide regimen.
Since approximately one third of patients in the diploid subgroup in this study who did not have an amplified NMYC locus have also died, it will be necessary to combine this genetic feature with other high-risk markers to produce a staging system that has a more optimal predictive strength. Apart from serum LDH levels, allelic loss of chromosome 1p (30) and increased levels of multidrug-resistance protein (29) have emerged as potentially useful indicators of poor-risk disease in patients without NMYC gene amplification. Whether these genetic features will significantly augment the features in our study awaits prospective testing in infants with neuroblastoma.
Some investigators have argued that stage D s neuroblastoma is in fact a relatively benign tumor that requires only conservative therapy (35) . In our experience, such tumors have essentially the same properties as other neuroblastomas in infants. We would emphasize that, within ploidy groups, the clinical outcome for stage D s tumors was not significantly different from that for tumors of other stages (Table 2) . Thus, we do not recommend a different management strategy for patients with tumors in this category, but rather suggest that they be treated according to ploidy findings and NMYC copy number.
Although cisplatin plus teniposide produced encouraging results in the cohort with diploid tumors who lacked NMYC gene amplification, there is still a need to define optimal therapy for these patients. Krestchmar et al. (36) at the Dana-Farber Cancer Institute reported an excellent outcome in infants with stage IV [stage D in the Pediatric Oncology Group system (15)] neuroblastoma treated with a six-drug regimen that included nitrogen mustard, doxorubicin, cisplatin, vincristine, cyclophosphamide, and imidazole carboxamide. However, neither ploidy nor NMYC determinations were made, so that the efficacy of this regimen in the treatment of patients with high-risk disease remains uncertain. A second concern is the irreversible ototoxicity and nephrotoxicity that can result from long-term administration of cisplatin to infants. To improve clinical outcome in neuroblastoma patients, the Pediatric Oncology Group is testing agents with known efficacy in older children with high-risk disease [carboplatin (37, 38) , etoposide (38) , and ifosfamide (37)] and is relying on granulocyte colony-stimulating factor to decrease toxicity and to allow more timely delivery of drugs. Whether these modifications will improve outcome in infants with diploid tumors and NMYC gene amplification remains unclear. If the prognosis for this subgroup continues to be poor, we would begin to consider these cases as counterparts of disseminated neuroblastoma in older children, which has resisted virtually all combination chemotherapy programs (26) . Thus, some of the innovative strategies currently being tried in children over 1 year of age-marrow-ablative chemotherapy with stem cell rescue (39) , immunotherapy (40) , and gene therapy (41)-may be justified for this very high-risk form of the disease.
